Role of AMP-Activated Protein Kinase Activators in Antiproliferative Multi-Drug Pituitary Tumour Therapies: Effects of Combined Treatments with Compounds Affecting the mTOR-p70S6 Kinase Axis in Cultured Pituitary Tumour Cells

Journal of Neuroendocrinology

Volumn 27, Issue 1, 2015, Pages 20-32

  Tulipano, G ^a   Faggi, L ^a   Cacciamali, A ^a   Spinello, M ^b   Cocchi, D ^a   Giustina, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Medical Department   (Italy)

Author keywords

AMP activated kinase; AMPK silencing; Cell growth; P70S6 kinase; Pituitary tumour; Rapamycin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, RAT; PF-4708671; PIPERAZINE DERIVATIVE; RAPAMYCIN; RIBONUCLEOTIDE; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECTS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PITUITARY NEOPLASMS; RAT; TUMOR CELL LINE;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ENZYME ACTIVATION; IMIDAZOLES; PHOSPHORYLATION; PIPERAZINES; PITUITARY NEOPLASMS; RATS; RIBONUCLEOTIDES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84919475379     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/jne.12231     Document Type: Article

References (37)

1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006; 65: 265-273.
2. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A. Acromegaly Consensus Group 2009 Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94: 1509-1517.
3. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts SW, Casanueva PP, Trainer P, Ghigo E, Ho K, Melmed S. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-3148.
4. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 2012; 7: e36411.
5. Towler MC, Hardie GD. AMP-activated protein kinase in metabolic control and insulin signalling. Circ Res 2007; 100: 328-341.
6. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, Alessi DR, Hardie DG. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
7. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13: 2004-2008.
8. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574: 63-71.
9. Guo D, Cloughesy TF, Radu CG, Mischell PS. AMPK: a metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle 2010; 9: 211-212.
10. Young ME, Radda GK, Leighton B. Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR-an activator of AMP-activated protein kinase. FEBS Lett 1996; 382: 43-47.
11. Tulipano G, Faggi L, Losa M, Mortini P, Spinello M, Sibilia V, Pagani F, Cocchi D, Giustina A. Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells. Mol Cell Endocrinol 2013; 365: 197-206.
12. Tulipano G, Giovannini M, Spinello M, Sibilia V, Giustina A, Cocchi D. AMP-activated protein kinase regulates normal rat somatotroph cell function and growth of rat pituitary adenomatous cells. Pituitary 2011; 14: 242-252.
13. Tulipano G, Faggi L, Sibilia V, Giustina A. Points of integration between the intracellular energy sensor AMP-activated protein kinase (AMPK) activity and the somatotroph axis function. Endocrine 2012; 42: 292-298.
14. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8: 733-741.
15. Bénéteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, Marchetti S, Cornille A, Carles M, Ricci JE. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl Acad Sci USA 2012; 109: 20071-20076.
16. Dworakowska D, Wlodek E, Leontiou CA, Igreia S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 2009; 2009: 1329-1338.
17. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 2009; 16: 1017-1027.
18. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, degli Uberti EC. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2010; 95: 968-976.
19. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010; 70: 666-674.
20. Cuny T, Gerard C, Saveanu A, Barlier A, Enjalbert A. Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy. Ann NY Acad Sci 2011; 1220: 60-70.
21. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM. Limitations in small intestinal neuroendocrine tumor therapy by mTOR kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 2011; 117: 4141-4154.
22. Passariello CL, Zini M, Nassi PA, Pignatti C, Stefanelli C. Upregulation of SIRT1 deacetylase in phenylephrine-treated cardiomyoblasts. Biochem Biophys Res Commun 2011; 407: 512-516.
23. Miller M, Chen S, Woodliff J, Kansra S. Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells. Endocrinology 2008; 149: 4158-4167.
24. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm Stat 2011; 10: 128-134.
25. Conejo R, Lorenzo M. Insulin signalling leading to proliferation, survival and membrane ruffling in C2C12 myoblats. J Cell Physiol 2001; 187: 96-108.
26. Tulipano G, Faggi L, Cacciamali A, Spinello M, Cocchi D, Giustina A. Interplay between the intracellular energy sensor AMP-activated protein kinase (AMPK) and the estrogen receptor activities in regulating rat pituitary tumor cell (GH3) growth in vitro. Pituitary 2014; 17: 203-209.
27. Pearce LR, Alton GR, Richte DT, Kath JC, Lingardo L, Chapman J, Hwang C, Alessi DR. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 2010; 431: 245-255.
28. Jin J, Mullen TD, Hou Q, Bielawski J, Bielawska A, Zhang X, Obeid LM, Hannun YA, Hsu YT. AMPK inhibitor compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J Lipid Res 2009; 50: 2389-2397.
29. Vucicevic L, Misirkic M, Janjetovic K, Vilimanovich U, Sudar E, Isenovic E, Prica M, Harhaji-Trajkovic L, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy 2011; 7: 40-50.
30. Saito S, Furuno A, Sakurai J, Park HR, Shin-ya K, Tomida A. Compound C prevents the unfolded protein response during glucose deprivation through a mechanism independent of AMPK and BMP signalling. PLoS ONE 2012; 7: e45845.
31. Liu X, Chhipa RR, Nakano I, Dasgupta B. The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther 2014; 13: 586-605.
32. Korsse SE, Peppelenbosch MP, van Veelen W. Targeting LKB1 signalling in cancer. Biochim Biophys Acta 2013; 1835: 194-210.
33. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-590.
34. Santidrian AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias M, Campas C, Gonzalez-Barca E, Alonso E, Labi V, Viollet B, Benito A, Pons G, Villunger A, Gil J. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood 2010; 116: 3023-3032.
35. Watters JJ, Chun TY, Kim YN, Bertics PJ, Gorski J. Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol Endocrinol 2000; 14: 1872-1881.
36. Rubinfeld H, Shimon I. PI3K/Akt/mTOR and Raf/MEK/ERK signalling pathways perturbations in non-functioning pituitary adenomas. Endocrine 2012; 42: 285-291.
37. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009; 33: 327-347.